Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults

نویسندگان

  • C A Green
  • E Scarselli
  • M Voysey
  • S Capone
  • A Vitelli
  • A Nicosia
  • R Cortese
  • A J Thompson
  • C S Sande
  • Catherine de Lara
  • P Klenerman
  • A J Pollard
چکیده

INTRODUCTION Respiratory syncytial virus (RSV) infection causes respiratory disease throughout life, with infants and the elderly at risk of severe disease and death. RSV001 is a phase 1 (first-in-man), open-label, dose-escalation, clinical trial of novel genetic viral-vectored vaccine candidates PanAd3-RSV and modified vaccinia virus Ankara (MVA)-RSV. The objective of RSV001 is to characterise the (primary objective) safety and (secondary objective) immunogenicity of these vaccines in healthy younger and older adults. METHODS AND ANALYSIS Heterologous and homologous 'prime'/boost combinations of PanAd3-RSV and single-dose MVA-RSV are evaluated in healthy adults. 40 healthy adults aged 18-50 years test one of four combinations of intramuscular (IM) or intranasal (IN) PanAd3-RSV prime and IM PanAd3 or IM MVA-RSV boost vaccination, starting at a low dose for safety. The following year an additional 30 healthy adults aged 60-75 years test either a single dose of IM MVA-RSV, one of three combinations of IN or IM PanAd3-RSV prime and PanAd3-RSV or MVA-RSV boost vaccination used in younger volunteers, and a non-vaccinated control group. Study participants are self-selected volunteers who satisfy the eligibility criteria and are assigned to study groups by sequential allocation. Safety assessment includes the daily recording of solicited and unsolicited adverse events for 1 week after vaccination, as well as visit (nursing) observations and safety bloods obtained at all scheduled attendances. Laboratory measures of RSV-specific humoral and cellular immune responses after vaccination will address the secondary end points. All study procedures are performed at the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford, UK. ETHICS AND DISSEMINATION RSV001 has clinical trial authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA) and ethics approval from NRES Berkshire (reference 13/SC/0023). All study procedures adhere to International Conference on Harmonisation (ICH) Good Clinical Practice guidelines. The results of the trial are to be published in peer-reviewed journals, conferences and academic forums. TRIAL REGISTRATION NUMBER NCT01805921.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates

Respiratory Syncytial Virus (RSV) is a leading cause of severe respiratory disease in infants and the elderly. No vaccine is presently available to address this major unmet medical need. We generated a new genetic vaccine based on chimpanzee Adenovirus (PanAd3-RSV) and Modified Vaccinia Ankara RSV (MVA-RSV) encoding the F, N, and M2-1 proteins of RSV, for the induction of neutralizing antibodie...

متن کامل

Prevalence of Respiratory Syncytial Virus, Adenovirus and Rhinovirus in Patients with flu-like symptoms Admitted to Mazandaran Province Health Centers in north of Iran – a cross–sectional study

Background: The main viral causes of acute respiratory diseases (ARDs) include influenza viruses A and B, respiratory syncytial virus (RSV), adenovirus (ADV), rhinovirus, and parainfluenza viruses (PIV). This study aimed to investigate the prevalence of respiratory RSV, ADV and rhinovirus in patients with flu-like symptoms admitted to Mazandaran province health centers in north of Iran. Metho...

متن کامل

Placental Transfer of Respiratory Syncytial Virus-Specific IgG in Iranian Mothers

Background: Respiratory Syncytical virus infection is the most common cause of bronchiolitis and viral pneumonia in infancy. Objective: To investigate the placental transfer of RSV-specific IgG in Iranian mothers. Methods: The antibodies were measured in sera of 146 mother/newborn pairs using a commercially available indirect Enzyme Linked Immunosorbent Assay (ELISA). The studied subjects were ...

متن کامل

A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant

BACKGROUND  Respiratory syncytial virus (RSV) is a leading cause of childhood bronchiolitis and pneumonia, particularly in early infancy. Immunization of pregnant women could boost preexisting immune responses, providing passive protection to newborns through placental transfer of anti-RSV antibody. METHODS  In this first-in-humans clinical trial of a purified recombinant RSV protein F vaccin...

متن کامل

The Frequency Distribution of Parainfluenza, Adeno and Respiratory Syncytial Virus Infections in Children below 2 Years Old with Bronchiolititis, by Multiplex Polymerase Chain Reaction Method, Afzalipoor Hospital, Kerman, 2006

Background & Aims: Acute respiratory infections are common cause of mortality during childhood. This study was designed to determine the incidence of adenovirus, parainfluenza virus and respiratory syncytial virus in respiratory infections by Multiplex PCR method. Methods: This study included 168 children under 2 years of age with clinical diagnosis of bronchiolitis. Nasopharyngeal specimens we...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 5  شماره 

صفحات  -

تاریخ انتشار 2015